Virtual Library
Start Your Search
N. Palazón Carrión
Author of
-
+
P2.03 - Chemotherapy/Targeted Therapy (ID 704)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.03-051 - The Impact of EGFR Mutations. Treatment with ITKs in Non Small Cell Lung Cancer Patients (ID 10302)
09:30 - 09:30 | Author(s): N. Palazón Carrión
- Abstract
Background:
Patients with advanced stage of non small cell lung cancer (NSCLC) have been historically treated with a limited number of cycles of first-line chemotherapy, with platinum-doublets as the most commonly used regimen, after which, those with tumour response or stable disease are observed for evidence of disease progression; progression is followed by second-line therapy in proper patients. In patients with advanced NSCLC harboring EGFR mutations, the use of EGFR TKIs in first-line treatment has shown a large PFS benefit with almost no toxicity when compared with chemotherapy. For patients with lung adenocarcinoma and activating EGFR mutations who received EGFR TKIs median overall survival (OS) ranges between 24 and 30 months contrasts with the plateau of 10 months reached with first line platinum-based chemotherapy in populations not selected by molecular profiling.
Method:
We analyze all patients attended in our hospital with NSCLC, who had received EGFR-TKI since 2010 to 2015 when hoarbouring EGFR mutation. For descriptive purposes, continuous variables were summarized as arithmetic means, medians and standard deviations, and categorical variables were reported as proportions with 95% confidence intervals (95% CI). PFS and OS were measured from the day of EGFR TKI treatment to the date of progression or death, respectively, and analyzed with the Kaplan-Meier technique.
Result:
The amount of patients were 46. Six types of EGFR gene mutations were found: delection in exon 19, exon 18 (G719), exon 20 (T790 and S768I ) and in exon 21 (L861Q and L858R). Two patients were combinations of G719 and L861Q, the third was a combination of G719 plus S768I, and the fourth was a combination of delection in 19 exon and T790 mutation. 13 patients (24.5%) could recieve second and furthers lines of therapy after EGFR ITKs, including: chemotherapy, immunotherapy and second generation EGFR TKIs. PFS was 9,98 months [4,7-15,25; IC95%.] OS was 23,45 months [11,26-35,6; IC 95%]
Conclusion:
The outcome of this study is to describe patient population receiving EGFR-TKIs. As expected most of them harbored the common sensitizing EGFR mutations L858R and delection in exon 19;both were higher in women and specially L858R mutation in non smokers. Nowadays treatment of patients with advanced NSCLC should be individualized, based on the molecular and histological features of their tumour. When harbouring an activating EGFR mutation, first-line treatment should be with an EGFR TKI.
